William F. C. Rigby - Concepedia

Author

William F. C. Rigby

Also Known As

Norman B Gaylis, Rigby, William, Rigby, William F. C., W F C Rigby, W F Rigby, W Rigby, W. F. C. Rigby, W. Rigby, W.F. Rigby, W.F.C. RIGBY

125

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

Dartmouth College Dartmouth–Hitchcock Medical Center White River Junction VA Medical Center Charité - Universitätsmedizin Berlin Roche (United Kingdom)

About

William F. C. Rigby is an author at Dartmouth College specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.1K
2	Cell Biology	7	7	687
3	Natural Sciences	2	2	272
4	Engineering	1	1	36
5	Social Sciences	1	1	16

William F. C. Rigby

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
MK2‐induced tristetraprolin:14‐3‐3 complexes prevent stress granule association and ARE‐mRNA decay Georg Stoecklin, Tiffany Stubbs, Nancy Kedersha, The EMBO Journal	2004	503
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors Dafna D. Gladman, William F. C. Rigby, Valderílio Feijó Azevedo, New England Journal of Medicine	2017	494
Glyceraldehyde-3-phosphate Dehydrogenase Selectively Binds AU-rich RNA in the NAD+-binding Region (Rossmann Fold) Eszter Nagy, William F. C. Rigby Journal of Biological Chemistry	1995	359
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study Josef S Smolen, Aileen L. Pangan, Paul Emery, The Lancet Rheumatoid DisorderRheumatologyDouble-blind Phase 3Rheumatic DiseasesPharmacology	2019	348
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) P. Emery, Atul Deodhar, William F. C. Rigby, Annals of the Rheumatic Diseases	2010	345
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial Paul P. Tak, William F. C. Rigby, Andrea Rubbert‐Roth, Annals of the Rheumatic Diseases	2010	300
Association of heterogeneous nuclear ribonucleoprotein A1 and C proteins with reiterated AUUUA sequences. B. JoNell Hamilton, Eszter Nagy, James S. Malter, Journal of Biological Chemistry GeneticsImmunologyMolecular BiologyAuuua SequencesProtein Synthesis	1993	211
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial Gerd R Burmester, William F. C. Rigby, Ronald van Vollenhoven, Annals of the Rheumatic Diseases	2015	193
The RGG Domain in hnRNP A2 Affects Subcellular Localization Ralph C. Nichols, X.W. Wang, Jie Tang, Experimental Cell Research Signal TransductionSignaling PathwayRgg DomainCellular BiochemistryMedicine	2000	169
The Role of mRNA Turnover in the Regulation of Tristetraprolin Expression: Evidence for an Extracellular Signal-Regulated Kinase-Specific, AU-Rich Element-Dependent, Autoregulatory Pathway Seth A. Brooks, John E. Connolly, William F. C. Rigby The Journal of Immunology	2004	145

Page 1